Mabion is a Polish biopharmaceutical company established in 2007 that provides end-to-end contract production and development services with a specific focus on monoclonal antibodies. Mabion’s capabilities begin with drug design and continue through GMP manufacturing of drug substance and drug product. Mabion has recently changed their strategy from being a biopharmaceutical company to becoming a standalone CDMO offering extensive services, including cell line development, manufacturing, GMP/GLP analytical services, process development, aseptic fill/finish, drug characterization, and regulatory support.